Tag: score

FLORENCE, Italy and NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, announced that new data related to the pivotal Phase 3 SENTRY trial will be presented as a late-breaking oral at The European Hematology Association (EHA) 2026 Congress.

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

New York City, June 12, 2026 (GLOBE NEWSWIRE) --

A new reputable online betting site in 2026 for players to bet on the FIFA World Cup 2026. Zizobet Casino has a fast registration process and offers a great welcome bonus for new players. Please read our detailed review.

ORMOND BEACH, Fla., June 12, 2026 (GLOBE NEWSWIRE) -- PlanetBids today announced that it has been named to Inc.’s 2026 Best Workplaces list for the second straight year. Each year, Inc. Magazine honors American companies that have built exceptional workplaces and vibrant cultures that support their teams and businesses, whether in-person, remote, or hybrid.

Inc. evaluates and measures applicants on elements such as management effectiveness, perks, professional development, and overall company culture. A detailed employee survey conducted over a period of March 4 to March 13, 2026 and a study of each company’s benefits over a period of November 2025 to February 2026, both conducted by Quantum Workplace, determine a company’s overall score. PlanetBids is honored to be included among the 507 companies recognized this year.

Founded in 2000, PlanetBids has been a fully remote/hybrid-optional company since 2020, with offices in Studio City, Calif. and Ormond Beach, Fla. and team members located across 19 states. The company was acquired by Capstreet, a Houston-based private equity firm, from co-founders Arpie and Alan Zavian, in October 2023.

"Being recognized by Inc. as one of the Best Workplaces for the second consecutive year is an incredible honor and a reflection of what makes PlanetBids truly special: our people," says David DiGiacomo, Chief Executive Officer at PlanetBids. "As a primarily remote company, we believe we’re proving that culture isn’t built by sharing an office; it’s built by sharing a mission, values, trust, and a commitment to each other’s success. This recognition belongs to every member of our team who shows up each day with passion, curiosity, and a desire to make a difference for our customers and one another."

PlanetBids champions a culture built around five core values that guide how the team works, grows, and supports one another:

A 96-engagement score and 100% highly engaged workforce reflect a culture united around helping enterprises ensure their data is ready to fuel AI

Basel, June 12, 2026 – Novartis today presented data from the RemIND trial at the European Academy of Allergy and Clinical Immunology (EAACI) Congress showing that Rhapsido^®  (remibrutinib) met its primary endpoints across the three most common chronic inducible urticaria (CIndU) subtypes, becoming the first-ever treatment to demonstrate efficacy in a global Phase III CIndU clinical trial⁷. In the RemIND trial, higher rates of complete responses were observed at week 12, with responses seen as early as week 2 in two subtypes. These results demonstrate that Rhapsido may provide sustained relief for patients whose disease remains inadequately controlled after treatment with second-generation H1-antihistamines⁷.

“Chronic inducible urticaria (CIndU) is a form of chronic hives in which everyday triggers—such as pressure, heat, cold, or sunlight—can lead to itchy wheals, and there are currently no approved targeted treatment options,” said Prof. Dr. med. Martin Metz, Deputy Director, Institute of Allergology, Charité–Universitätsmedizin Berlin, Germany. “The RemIND results across the three most common CIndU subtypes highlight the potential of Rhapsido as an important new treatment option for patients with significant unmet need.”

The three most prevalent CIndU subtypes are symptomatic dermographism (SD), cold urticaria, and cholinergic urticaria, with SD being the most common⁸. Novartis has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Rhapsido for the treatment of SD subtype and will continue additional filings to health authorities globally throughout 2026. Rhapsido is approved for use in the U.S., European Union, China and several other countries for the treatment of chronic spontaneous urticaria (CSU), in adult patients with inadequate response to H1-antihistamines.

“Rhapsido significantly improves symptom control for patients living with the three most common subtypes of chronic inducible urticaria, and it has the potential to become the first approved targeted therapy. This is a major step forward for CIndU patients who have limited options,” said Angelika Jahreis, Global Head, Immunology Development, Novartis. “The CIndU data presented today are consistent with Rhapsido’s proven efficacy and favorable safety profile in chronic spontaneous urticaria and demonstrate Novartis’ commitment to developing truly meaningful innovation for patients with complex immune-mediated diseases.”

Primary endpoint results at Week 12 in the RemIND trial¹